The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
References
(i) This compound is an investigational agent. Its efficacy and safety have not yet been fully established.
(1). Spicer J et al. Activity of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor, in NSCLC with mutated EGFR. Abstract D7-02. Presented at WCLC September 6 2007.
(2). Solca F et al. AACR-NCI-EORTC Proceedings, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2005;118 (Abstract A244).
(3). Solca F et al. AACR-NCI-EORTC Proceedings, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2005;118 (Abstract A242).
(4). Data on file, Boehringer Ingelheim
(5). Hilberg F et al. Eur J Cancer Suppl. 2004;2:50.
(6). Hanna N et al. A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with NSCLC. Abstract P3-091. Presented at WCLC September 5 2007.
(7). Camidge R et al. A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced NSCLC. Abstract P3-138. Presented at WCLC September 5 2007.
(8). Reck M et al. Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed, advanced NSCLC. Abstract B1-03. Presented at WCLC September 4 2007.
For more information please visit http://www.boehringer-ingelheim.com.
Contact: Julia Meyer-Kleinmann, R&D Communications, Boehringer Ingelheim GmbH, Tel.: +49-6132-77-8271, Email: M-Kleinmann@boehringer-ingelheim.com
